Search
Substantial spatial clustering of notified tuberculosis was detected at region, zone and district level in Ethiopia
Palivizumab appeared effective for reducing virologically confirmed respiratory syncytial virus in this high-risk cohort
Influenza vaccination recommendation by children’s hospital physicians and previous vaccine receipt in hospital was associated with vaccine uptake
A significant reduction in severe influenza was observed in Australian children, possibly contributed to by improved vaccine coverage and high vaccine effectiveness
Children with birth defects experience higher rates of hospitalisation for ALRIs before age 2 years than children with no birth defects.
The aim of this study was to use total-population based data on an otherwise healthy population of children to assess the relationship between early...
The authors previously reported an increased risk of hospitalisation for acute lower respiratory infection up to age 2 years in children delivered by...
Invasive group A streptococcal infection in Australian children is frequently severe and has a high long-term morbidity burden
Australian authorities made COVID-19 vaccines available for children aged under 5 years old with serious comorbidities in August 2022. There is presently no universal programme for young children, but crucial to any rollout's success is whether parents are motivated and able to vaccinate. By examining parents' vaccine intentions, this study aims to inform current and future COVID-19 vaccine roll-outs for children aged under 5 years.
Vaccine development and implementation decisions need to be guided by accurate and robust burden of disease data. We developed an innovative systematic framework outlining the properties of such data that are needed to advance vaccine development and evaluation, and prioritize research and surveillance activities.